|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal Susitarimą)
| (51) | INT.CL. | A61K 38/18 | |
| A61P 7/06 | |||
| A61K 38/20 | |||
| A61K 47/48 | |||
| A61K 39/395 |
| (11) | Patento numeris | 1330260 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 01992582.5 |
| Europos patento paraiškos padavimo data | 2001-10-30 | |
| (97) | Europos patento paraiškos paskelbimo data | 2003-07-30 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2014-05-07 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (86) | Numeris | PCT/US2001/046205 |
| Data | 2001-10-30 |
| (87) | Numeris | WO 2002/036152 |
| Data | 2002-05-10 |
| (30) | Numeris | Data | Šalis |
| 244792 P | 2000-10-31 | US | |
| 969739 | 2001-10-02 | US |
| (72) |
KAY, Jonathan, US
MCCABE, Dorothy, US
NEWMARK, Richard, US
COCCIA, Marco, A., US
|
| (73) |
AMGEN INC.,
One Amgen Center Drive, Thousand Oaks, CA 91320-1799,
US
|
| (54) | USE OF IL-1 INHIBITORS AND TNF ANTAGONISTS, PARTIALLY IN COMBINATION WITH RECOMBINANT ERYTHROPOIETINS, FOR THE TREATMENT OF ANEMIA |
| USE OF IL-1 INHIBITORS AND TNF ANTAGONISTS, PARTIALLY IN COMBINATION WITH RECOMBINANT ERYTHROPOIETINS, FOR THE TREATMENT OF ANEMIA |